Agilent Technologies (NYSE:A) Now Covered by Stifel Nicolaus

Equities research analysts at Stifel Nicolaus started coverage on shares of Agilent Technologies (NYSE:A) in a research report issued to clients and investors on Thursday, MarketBeat reports. The brokerage set a “hold” rating and a $85.00 price target on the medical research company’s stock. Stifel Nicolaus’ target price suggests a potential upside of 8.61% from the company’s current price.

Other research analysts have also issued research reports about the company. Piper Jaffray Companies raised their price objective on Agilent Technologies from $83.00 to $86.00 and gave the company an “overweight” rating in a report on Thursday, August 15th. UBS Group lowered Agilent Technologies from a “buy” rating to a “neutral” rating and set a $82.00 price target on the stock. in a report on Friday, October 18th. Zacks Investment Research lowered Agilent Technologies from a “buy” rating to a “hold” rating and set a $75.00 price target on the stock. in a report on Monday, August 19th. Robert W. Baird reiterated an “outperform” rating and set a $82.00 price target (up previously from $79.00) on shares of Agilent Technologies in a report on Thursday, August 15th. Finally, Barclays reduced their price target on Agilent Technologies from $78.00 to $76.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 9th. Seven analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Agilent Technologies presently has an average rating of “Buy” and an average price target of $84.08.

Shares of A stock opened at $78.26 on Thursday. The stock’s fifty day moving average is $75.65 and its two-hundred day moving average is $72.85. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.72 and a current ratio of 2.13. The firm has a market capitalization of $23.88 billion, a P/E ratio of 28.05, a PEG ratio of 1.92 and a beta of 1.42. Agilent Technologies has a fifty-two week low of $62.00 and a fifty-two week high of $82.27.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Wednesday, August 14th. The medical research company reported $0.76 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.04. The company had revenue of $1.27 billion for the quarter, compared to analyst estimates of $1.24 billion. Agilent Technologies had a return on equity of 20.00% and a net margin of 21.06%. The firm’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.67 EPS. On average, equities analysts forecast that Agilent Technologies will post 3.08 earnings per share for the current year.

In related news, CEO Michael R. Mcmullen sold 24,635 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $77.50, for a total transaction of $1,909,212.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Heidi Fields sold 4,000 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $70.96, for a total value of $283,840.00. The disclosure for this sale can be found here. Insiders have sold a total of 32,635 shares of company stock valued at $2,507,293 over the last three months.

Several large investors have recently modified their holdings of the stock. Fulton Bank N.A. grew its stake in shares of Agilent Technologies by 3.8% in the second quarter. Fulton Bank N.A. now owns 5,235 shares of the medical research company’s stock worth $391,000 after acquiring an additional 194 shares during the period. Sanders Morris Harris LLC bought a new stake in shares of Agilent Technologies in the second quarter worth approximately $285,000. Hexavest Inc. bought a new stake in shares of Agilent Technologies in the second quarter worth approximately $1,783,000. LGT Capital Partners LTD. bought a new stake in shares of Agilent Technologies in the second quarter worth approximately $15,194,000. Finally, AMF Pensionsforsakring AB grew its position in Agilent Technologies by 190.3% during the second quarter. AMF Pensionsforsakring AB now owns 17,420 shares of the medical research company’s stock valued at $1,301,000 after buying an additional 11,420 shares during the period.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

Read More: The four types of profit margin

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.